US plans for reforming biopharma pricing at home and abroad

12 February 2018

On Friday, the US Council of Economic Advisers (CEA) released a report on how the government can help to effectively reduce the prices of lifesaving drugs while stimulating innovation in the pharmaceutical industry.

The 30-page White House document is floating numerous ideas for curbing drug prices, including weakening the power of pharmacy benefit managers, reorganizing Medicare reimbursement and shaking up trade policy with countries that arguably underpay for medicines, as well as how the Food and Drug Administration approves and regulates drugs, saying the federal programs and agencies could create a more level playing field for drugmakers.

Read the full report here.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK